Antengene grants UCB worldwide exclusive rights to develop, manufacture and commercialize ATG-201, a CD19/CD3 bispecific T-cell engager (TCE) antibody, targeting B cell-related autoimmune ...

Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular ...

A study in Clinical Infectious Diseases ties Legionella links pneumonia to high 30-day death rates, especially in patients who are older or have underlying cirrhosis, a weakened immune system, or ...

A look at the biologics, gene therapies, and vaccines most likely to reshape care —and manufacturing—in the year ahead.

The American Academy of Pediatrics generally recommends RSV immunization for infants under eight months old born during or entering their first RSV season if their mothers weren’t vaccinated during ...

During the quarter, Baron Health Care Fund added seven new positions and exited ten positions, bringing the number of ...

Patients with new-onset alopecia areata are at increased 10-year risk of developing several immune-mediated inflammatory diseases, according to a study.

During the fourth quarter of 2025, the Fund returned 13.10% (Institutional Shares), outperforming the Russell 3000 Index ...

Initial $50M Series A investment from founding investor RTW Investments Proceeds will fund clinical development of PRO-203 in systemic sclerosis (SSc) and multiple additional severe autoimmune ...

Multiplex assay tech detects multi-biomolecules in single samples on xMAP/CBA, with high sensitivity and consistency ...

Supplements, surprising treatments, immunity-boosting vaccines and even exercises can help the immune system do its job ...